Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers

Abstract

Assessment of SBS and ID signatures can discriminate CRCs from biallelic <i>MUTYH</i> carriers and MMR PV carriers from non-carriers with high accuracy, demonstrating utility as a potential diagnostic and variant classification tool.